Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
J Acquir Immune Defic Syndr ; 57(4): 261-4, 2011 Aug 01.
Article in English | MEDLINE | ID: mdl-21546848

ABSTRACT

Fluctuations in susceptibility to HIV or SHIV during the menstrual cycle are currently not fully documented. To address this, the time point of infection was determined in 19 adult female pigtail macaques vaginally challenged during their undisturbed menstrual cycles with repeated, low-dose SHIV(SF162P3) exposures. Eighteen macaques (95%) first displayed viremia in the follicular phase, as compared with 1 macaque (5%) in the luteal phase (P < 0.0001). Due to a viral eclipse phase, we estimated a window of most frequent virus transmission between days 24 and 31 of the menstrual cycle, in the late luteal phase. Thus, susceptibility to vaginal SHIV infection is significantly elevated in the second half of the menstrual cycle when progesterone levels are high and when local immunity may be low. Such susceptibility windows have been postulated before but not definitively documented. Our data support the findings of higher susceptibility to HIV in women during progesterone-dominated periods including pregnancy and contraceptive use.


Subject(s)
Luteal Phase/physiology , Simian Acquired Immunodeficiency Syndrome/transmission , Vagina/virology , Animals , Disease Susceptibility , Female , HIV-1 , Macaca nemestrina , Pregnancy , Simian Immunodeficiency Virus , Viral Load , Viremia
2.
J Acquir Immune Defic Syndr ; 53(5): 574-81, 2010 Apr.
Article in English | MEDLINE | ID: mdl-20164782

ABSTRACT

Animal models for research on susceptibility to HIV are currently not available. Here we explore whether a macaque model of repeated low-dose rectal or vaginal virus challenges could be employed. We tested the hypothesis that susceptibility to Simian HIV is not merely stochastic in this model but rather is associated with identifiable host factors. Forty macaques required a median of 3.5 SHIVSF162P3 challenges for infection. We studied the association of their susceptibility with 13 predisposing plasma cytokines/chemokines (RANTES, Eotaxin, monocyte chemoattractant protein (MCP)-1, IL-7, MIP-1beta, TNF-alpha, MIP-1alpha, granulocyte colony-stimulating factor, IL-8, interferon-gamma, IL-17, IL-1beta, IL-6). Higher plasma RANTES, IL-8, and Eotaxin were associated with lower susceptibility, that is, higher resistance to infection. In a group of macaques with low IL-8 and RANTES, a median 3 exposures were required to infect; whereas, when either IL-8 or RANTES were high, a median 12 exposures were required. Thus, susceptibility was associated with identifiable discrete host factors and was not stochastic. In addition, the macaque model identified key human resistance factors (RANTES, Eotaxin), but also revealed a novel association with resistance (IL-8). Future direct evaluation of these or other factors in the animal model may be beneficial for developing new immunomodulation strategies for HIV prevention.


Subject(s)
Chemokine CCL11/immunology , Chemokine CCL5/immunology , Interleukin-8/immunology , Simian Acquired Immunodeficiency Syndrome/immunology , Simian Immunodeficiency Virus/immunology , Animals , Chemokine CCL11/blood , Chemokine CCL5/blood , Disease Models, Animal , Female , Interleukin-8/blood , Kaplan-Meier Estimate , Macaca mulatta , Macaca nemestrina , Male , RNA, Viral/blood , Simian Acquired Immunodeficiency Syndrome/virology , Viremia/immunology
3.
Antimicrob Agents Chemother ; 51(6): 1972-8, 2007 Jun.
Article in English | MEDLINE | ID: mdl-17404008

ABSTRACT

Topical microbicides (cellulose acetate 1,2 benzene dicarboxylate [CAP], PRO 2000, SPL7013, and UC781) are being investigated to reduce the sexual transmission of human immunodeficiency virus type 1 (HIV-1). These products were shown to prevent the transfer of infectious HIV-1 from urogenital and colorectal epithelial cell lines to peripheral blood mononuclear cells. However, it was unclear if the topical microbicides rendered the virus noninfectious and/or reduced the binding to the epithelial cells. To test this, epithelial cells were cultured with HIV-1 in the presence or absence of topical microbicides or their placebos. The cells were washed, RNA lysates were made, and real-time PCR was performed for HIV-1. PRO 2000 and SPL7013 significantly (P < 0.0001) reduced the amount of bound HIV-1 to the colorectal epithelial cell line across clades A, B, C, and CRF01-AE. While none of the products reduced the binding of HIV-1 clades A and C to the urogenital cell line, CAP, PRO 2000, and SPL7013 significantly (P

Subject(s)
Anti-HIV Agents/pharmacology , Anti-Infective Agents, Local/pharmacology , Epithelial Cells/virology , HIV-1/drug effects , HIV-1/metabolism , Anilides/pharmacology , Caco-2 Cells , Cellulose/analogs & derivatives , Cellulose/pharmacology , Colon/cytology , Colon/virology , Dendrimers , Furans/pharmacology , Humans , Naphthalenesulfonates/pharmacology , Polylysine/pharmacology , Polymers/pharmacology , Rectum/cytology , Rectum/virology , Thioamides , Urogenital System/cytology , Urogenital System/virology
4.
Antimicrob Agents Chemother ; 51(5): 1770-9, 2007 May.
Article in English | MEDLINE | ID: mdl-17353237

ABSTRACT

A human cervical explant culture was utilized for the preclinical assessment of anti-human immunodeficiency virus type 1 (HIV-1) activity and tissue toxicity of formulated, candidate topical microbicides. Products tested included cellulose acetate 1,2-benzene dicarboxylate (CAP), a carrageenan-based product (PC-515), a naphthalene sulfonate polymer (PRO 2000), a lysine dendrimer (SPL7013), a nonnucleoside reverse transcriptase inhibitor (UC781), and an antimicrobial peptide (D2A21), along with their placebos. Cervical explants were cultured overnight with HIV-1 with or without product, washed, and monitored for signs of HIV-1 infection. HIV-1 infection was determined by p24gag levels in the basolateral medium and by immunohistochemical analysis of the explant. Product toxicity was measured by the MTT [1-(4,5-dimethylthiazol-2-yl)-3,5-diphenylformazan] assay and histology. CAP, PRO 2000, SPL7013, and UC781 consistently prevented HIV-1 infection in all explants tested. PC-515 and D2A21 prevented HIV-1 infection in 50% or fewer of the explants tested. Placebos did not prevent infection in any of the explants tested. With the exception of PRO 2000 (4%), the MTT assay and histological analysis of the other products and placebos showed minimal toxicity to the epithelium and submucosa. Collectively, these data suggest that this culture system can be used for evaluating the safety and efficacy of topical microbicides designed for vaginal use.


Subject(s)
Anti-HIV Agents/pharmacology , Anti-Infective Agents, Local/pharmacology , Cervix Uteri/virology , HIV-1/drug effects , Anti-Infective Agents, Local/toxicity , Cervix Uteri/drug effects , Female , Humans , Permeability
5.
J Infect Dis ; 192(9): 1545-56, 2005 Nov 01.
Article in English | MEDLINE | ID: mdl-16206069

ABSTRACT

A human colorectal explant culture was developed to assess the safety and efficacy of topical microbicides proposed for use in humans. Because any product marketed for vaginal application will likely be used for anal intercourse, it is important to evaluate these products in colorectal explant tissue. Microbicides tested included cellulose acetate 1,2-benzenedicarboxylate (CAP), PRO 2000, SPL7013, Vena Gel, and UC781, along with their accompanying placebos. Colorectal tissues were exposed to microbicides overnight and either fixed in formalin to evaluate toxicity by histological analysis or placed in 1-(4,5-dimethylthiazol-2-yl)-3,5-diphenylformazan (MTT) to quantitatively determine tissue viability. Histological analysis showed minimal toxicity for CAP, UC781, and Vena Gel. Shedding of epithelium with intact lamina propria occurred for the PRO 2000 and SPL7013 products, and shedding of epithelium and necrosis of the lamina propria occurred in explants cultured with nonoxynol-9. The MTT assay confirmed these results for PRO 2000 (4% and 0.5%), SPL7013 (and placebo), and nonoxynol-9 but also demonstrated reduced viability for CAP. However, viability of tissues treated with all products was not significantly different from that of the medium control. Efficacy of the microbicides was evaluated by measuring human immunodeficiency virus type 1 (HIV-1) infection of explants in the absence or presence of products. All microbicide formulations tested were highly effective in preventing HIV infection. However, explants treated with some of the placebo formulations also exhibited a lower level of infection. Most of the products developed for vaginal application showed minimal toxicity and were effective in reducing HIV-1 infection in colorectal tissues. These results suggest that this model is useful for evaluating the safety and efficacy of topical microbicides when used rectally.


Subject(s)
Anti-Infective Agents/pharmacology , Anti-Retroviral Agents/pharmacology , HIV Infections/prevention & control , HIV-1/drug effects , Intestinal Mucosa/drug effects , Anti-Retroviral Agents/toxicity , Cells, Cultured , Colon/drug effects , Colon/pathology , Drug Evaluation, Preclinical , HIV-1/genetics , HIV-1/isolation & purification , Humans , Intestinal Mucosa/pathology , Necrosis/pathology , Organ Culture Techniques
6.
Infect Immun ; 73(7): 4155-60, 2005 Jul.
Article in English | MEDLINE | ID: mdl-15972505

ABSTRACT

The objective of this study was to evaluate potential mechanisms of Trichomonas vaginalis involvement in human immunodeficiency virus type 1 (HIV-1) transmission. Polarized monolayer integrity of primary cervical and prostate epithelial cells or cell lines cultured with T. vaginalis was measured by monitoring transepithelium resistance. The effect of T. vaginalis isolates on HIV-1 passage through polarized epithelial cell monolayers was evaluated for HIV-1 p24gag in the basolateral supernatants. Coincubation with T. vaginalis isolates induced disruption of monolayer integrity and resulted in passage of virus to the basolateral side of the monolayer. Furthermore, there was isolate variability in which two isolates induced greater monolayer damage and increased HIV-1 passage than did the other two isolates. Coincubation of T. vaginalis isolates with acutely HIV-1-infected peripheral blood mononuclear cells enhanced HIV-1 replication. This enhancement was associated with cellular proliferation and activation, as well as with tumor necrosis factor alpha production. In contrast to the monolayer disruption, the effect of T. vaginalis on HIV-1 replication was not isolate dependent. Thus, two mechanisms have been identified that could contribute to the epidemiologic association of trichomoniasis with the sexual transmission of HIV-1. (i) T. vaginalis disruption of urogenital epithelial monolayers could facilitate passage of HIV-1 to underlying layers. (ii) Activation of local immune cells by T. vaginalis in the presence of infectious HIV-1 might lead to increased viral replication. Collectively, these data suggest the need for more vigilant efforts in the diagnosis and treatment of T. vaginalis in women and men, especially in countries with a high prevalence of HIV-1.


Subject(s)
Acquired Immunodeficiency Syndrome/transmission , Cervix Uteri/immunology , Epithelial Cells/immunology , HIV-1/physiology , Prostate/immunology , Sexually Transmitted Diseases/transmission , Trichomonas vaginalis/pathogenicity , Virus Replication , Animals , Cell Line , Cervix Uteri/virology , Epithelial Cells/physiology , Epithelial Cells/virology , Female , Humans , Male , Prostate/virology , Tumor Necrosis Factor-alpha/physiology
7.
Clin Diagn Lab Immunol ; 10(4): 715-7, 2003 Jul.
Article in English | MEDLINE | ID: mdl-12853410

ABSTRACT

A potential public health concern is the reported detection of the human T-lymphotropic virus (HTLV) tax gene in the lymphocytes of up to 11% of a low-risk group of New York City blood donors (NYBD). This study aimed to independently confirm the prevalence of HTLV tax sequences in 293 NYBD. All NYBD tested negative for antibodies to HTLV types 1 and 2 and HTLV Tax. HTLV tax sequences were not detected in the NYBD lymphocytes. These data demonstrate the lack of HTLV-1 tax in this group of NYBD at low risk for HTLV infection.


Subject(s)
Blood Donors , Genes, pX , HTLV-I Antibodies/blood , HTLV-I Infections/diagnosis , HTLV-II Antibodies/blood , HTLV-II Infections/diagnosis , Human T-lymphotropic virus 1/isolation & purification , Human T-lymphotropic virus 2/isolation & purification , Lymphocytes/virology , Adult , Antibody Specificity , Female , Gene Products, tax/immunology , HTLV-I Antibodies/immunology , HTLV-I Infections/blood , HTLV-I Infections/epidemiology , HTLV-II Antibodies/immunology , HTLV-II Infections/blood , HTLV-II Infections/epidemiology , Human T-lymphotropic virus 1/genetics , Human T-lymphotropic virus 1/immunology , Human T-lymphotropic virus 2/genetics , Human T-lymphotropic virus 2/immunology , Humans , Immunoenzyme Techniques , Male , New York City/epidemiology , Polymerase Chain Reaction , Prevalence , Risk Factors
8.
J Infect Dis ; 186(11): 1669-72, 2002 Dec 01.
Article in English | MEDLINE | ID: mdl-12447745

ABSTRACT

Human T cell lymphotropic virus type I (HTLV-I) is sexually transmitted. The purpose of this study was to determine the prevalence and risk factors for cervical shedding of HTLV-I DNA among Peruvian sex workers. HTLV tax DNA was detected in cervical specimens from 43 (68%) of 63 HTLV-I-infected sex workers and in samples obtained during 113 (52%) of 216 clinic visits between 1993 and 1997. Detection of HTLV DNA was associated with the presence of > or =30 polymorphonuclear cells (PMNs) within cervical mucus per 100x microscopic field (odds ratio [OR], 4.3, 95% confidence interval [CI], 1.8-10.1) and with the presence of cervical secretions (OR, 2.0; 95% CI 1.2-3.4). Hormonal contraceptive use (OR 1.7; 95% CI, 0.8-3.6) and concomitant cervical infection by Chlamydia trachomatis (OR, 1.5; 95% CI, 0.3-4.3) or Neisseria gonorrhoeae (OR, 1.1; 95% CI, 0.6-3.7) were not significantly associated with HTLV-I shedding. Our results suggest that cervicitis may increase cervical HTLV-I shedding and the sexual transmission of this virus.


Subject(s)
Cervix Uteri/virology , HTLV-I Infections/transmission , Human T-lymphotropic virus 1/physiology , Uterine Cervicitis/virology , Virus Shedding , Adult , Aged , DNA, Viral/analysis , Female , HTLV-I Antibodies/blood , HTLV-I Infections/virology , Human T-lymphotropic virus 1/isolation & purification , Humans , Middle Aged , Peru , Polymerase Chain Reaction , Prevalence , Risk Factors , Sex Work
SELECTION OF CITATIONS
SEARCH DETAIL
...